For research use only. Not for therapeutic Use.
SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC502μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents [1].
| Catalog Number | I036635 |
| CAS Number | 1030769-75-5 |
| Synonyms | 4-(benzimidazol-1-yl)-N-[4-(2-oxo-3,4-dihydro-1H-quinolin-6-yl)-1,3-thiazol-2-yl]benzamide |
| Molecular Formula | C26H19N5O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C26H19N5O2S/c32-24-12-8-17-13-18(7-11-20(17)28-24)22-14-34-26(29-22)30-25(33)16-5-9-19(10-6-16)31-15-27-21-3-1-2-4-23(21)31/h1-7,9-11,13-15H,8,12H2,(H,28,32)(H,29,30,33) |
| InChIKey | DXSMYUKZPWJQFM-UHFFFAOYSA-N |
| SMILES | C1CC(=O)NC2=C1C=C(C=C2)C3=CSC(=N3)NC(=O)C4=CC=C(C=C4)N5C=NC6=CC=CC=C65 |
| Reference | [1]. Zhang W, et al. Discovery of novel frizzled-7 inhibitors by targeting the receptor’s transmembrane domain. Oncotarget. 2017 Sep 6;8(53):91459-91470. |
